Trade Summary

1 week ago, Prasad Raju, serving as CFO at Crispr Therapeutics AG (CRSP), sold 10,000 shares at $55.95 per share, for a total transaction value of $559,549.00. Following this transaction, Prasad Raju now holds 6,767 shares of CRSP.

This sale represents a 60.00% decrease in Prasad Raju's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Monday, December 22, 2025 and publicly disclosed via SEC Form 4 filing on Tuesday, December 23, 2025, 1 day after the trade was made.

Crispr Therapeutics AG operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.